Biography

Dr Govender is a clinical investigator, safety officer and clinical research site leader in Gauteng, South Africa, with experience in phase I-IV HIV, TB and COVID-19 prevention trials in healthy adults (microbicides, vaccines); TB prevention therapy in adults, children and adolescents living with HIV; and analytical treatment interruption trials in adults with HIV.

Expertise

TB Diagnostics
Public Health

Key Impacts

Safety of the novel TB vaccine H107e/CAF®10b in BCGexposed, M.tuberculosis-uninfected adults in Gauteng, South Africa: First in human trial

H107e-antigen and CAF®10b adjuvant at two doses, individually or in combination, and H107e-antigen intranasally were well tolerated in South African BCG-exposed, Mtb-uninfected adults.

Source: Conference 2024